Sale

Parasitic Diseases Therapeutics Market

Global Parasitic Diseases Therapeutics Market Size, Forecast: By Type: Protozoa, Helminths, Ectoparasite; By Population Type: Children, Adults; By Drug Class: Anthelmintics, Antiprotozoals, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Patent Analysis; Supplier Landscape; 2024-2032

Global Parasitic Diseases Therapeutics Market Outlook

The global parasitic diseases therapeutics market size was valued at USD 1.79 billion in 2023. Rising disposable incomes, increasing population, and the rising prevalence of parasites are the driving factors of this market. The market is anticipated to grow at a CAGR of 5% during the forecast period 2024-2032 to reach a value of USD 2.77 billion by 2032.

 

Global Parasitic Diseases Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

Amebiasis, African sleeping disease, trichomoniasis, giardiasis, trypanosomiasis, leishmaniasis, and malaria are all parasitic diseases that need treatment. Based on the product, the parasitic diseases therapeutics market can be divided into:

  • Antiprotozoal Therapeutics
  • Anthelminthic Therapeutics
  • Scabicides And Pediculicides Therapeutics

The EMR report looks into the regional parasitic diseases therapeutics markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Parasitic Diseases Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

Protozoal, along with helminthic worm diseases, have raised the mortality and morbidity of prophylactic therapy. Preventive chemotherapy is used to monitor the spread within a population of helminthic infections. The high prevalence of malaria worldwide prompted researchers to develop different vaccines to prevent the disease from spreading. Researchers are also developing a variety of prophylactic vaccines to treat and prevent skin leishmaniasis and visceral leishmaniasis. The growing acceptance of these prophylactic vaccines for the prevention and control of parasite diseases is one of the key market developments on parasitic diseases, which would have a positive effect on the market growth.

The occurrence of protozoan, helminth, as well as ectoparasite infections, is rapidly rising. The number of individuals infected with whipworms and hookworms is increasing annually. The number of cases of African trypanosomiasis recorded has also increased considerably, particularly in countries in sub-Saharan Africa like Zambia, Tanzania, Uganda, and Malawi. Likewise, in parts of Central America, South America, and Mexico, the prevalence of Chagas disease is high. In addition, the prevalence of schistosomiasis is also rising globally. The increasing prevalence of these parasites will lead to a growing demand for the treatment of parasites. The antiprotozoal therapeutics segment accounted for the largest market share in 2020.

However, the challenges related to the discovery of antiparasitic drugs and disease diagnosis, increased drug resistance, lack of effective therapies, and side-effects may impede the development of the parasite diseases therapeutics industry in the coming years.

 

Global Parasitic Diseases Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global parasitic diseases therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • F. Hoffmann-La Roche
  • Novartis AG
  • GlaxoSmithKline PLC
  • Sanofi SA
  • Pfizer Inc.
  • Others

The EMR report gives an in-depth insight into the parasitic diseases therapeutics market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Population Type
  • Drug Class
  • Distribution Channel
  • Region
Breakup by Type
  • Protozoa
  • Helminths
  • Ectoparasite
Breakup by Population Type
  • Children
  • Adults
Breakup by Drug Class
  • Anthelmintics
  • Antiprotozoals
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche
  • Novartis AG
  • GlaxoSmithKline PLC
  • Sanofi SA
  • Pfizer Inc.
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Parasitic Diseases Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Parasitic Diseases Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Parasitic Diseases Epidemiology (2016-2031)
    5.3    Europe Parasitic Diseases Epidemiology (2016-2031)
    5.4    Asia-Pacific Parasitic Diseases Epidemiology (2016-2031)
    5.5    Latin America Parasitic Diseases Epidemiology (2016-2031)
    5.6    Middle East & Africa Parasitic Diseases Epidemiology (2016-2031)
6    Parasitic Diseases Therapeutics Market Overview 
    6.1    Parasitic Diseases Therapeutics Market Historical Value (2017-2023) 
    6.2    Parasitic Diseases Therapeutics Market Forecast Value (2024-2032)
7    Parasitic Diseases Therapeutics Market Landscape
    7.1    Parasitic Diseases Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Parasitic Diseases Therapeutics: Product Landscape
        7.2.1    Analysis by Type
        7.2.2    Analysis by Technology
8    Parasitic Diseases Therapeutics Market Dynamics
    8.1    Market Drivers and Constraints
    8.2    SWOT Analysis
    8.3    Porter’s Five Forces Model
    8.4    Key Demand Indicators 
    8.5    Key Price Indicators
    8.6    Industry Events, Initiatives, and Trends  
    8.7    Value Chain Analysis
9    Parasitic Diseases Therapeutics Market Segmentation
    9.1    Parasitic Diseases Therapeutics Market by Type
        9.1.1    Market Overview    
        9.1.2    Protozoa
        9.1.3    Helminths
        9.1.4    Ectoparasite
    9.2    Parasitic Diseases Therapeutics Market by Population Type
        9.2.1    Market Overview
        9.2.2    Children
        9.2.3    Adults 
    9.3    Parasitic Diseases Therapeutics Market by Drug Class
        9.3.1    Market Overview
        9.3.2    Anthelmintics
        9.3.3    Antiprotozoals
        9.3.4    Others
    9.4    Parasitic Diseases Therapeutics Market by Distribution Channel
        9.4.1    Market Overview
        9.4.2    Hospital Pharmacies
        9.4.3    Retail Pharmacies
        9.4.4    Online Pharmacies
        9.4.5    Others 
    9.5    Parasitic Diseases Therapeutics Market by Region
        9.5.1    Market Overview
        9.5.2    North America
        9.5.3    Europe 
        9.5.4    Asia Pacific
        9.5.5    Latin America
        9.5.6    Middle East and Africa
10    North America Parasitic Diseases Therapeutics Market
    10.1    Market Share by Country
    10.2    United States of America
    10.3    Canada
11    Europe Parasitic Diseases Therapeutics Market
    11.1    Market Share by Country
    11.2    United Kingdom
    11.3    Germany
    11.4    France
    11.5    Italy
    11.6    Others
12    Asia Pacific Parasitic Diseases Therapeutics Market
    12.1    Market Share by Country
    12.2    China
    12.3    Japan
    12.4    India
    12.5    ASEAN
    12.6    Australia
    12.7    Others
13    Latin America Parasitic Diseases Therapeutics Market
    13.1    Market Share by Country
    13.2    Brazil
    13.3    Argentina
    13.4    Mexico
    13.5    Others
14    Middle East and Africa Parasitic Diseases Therapeutics Market
    14.1    Market Share by Country
    14.2    Saudi Arabia
    14.3    United Arab Emirates
    14.4    Nigeria
    14.5    South Africa
    14.6    Others
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    INDIA CDSCO
        15.1.4    JAPAN PMDA
        15.1.5    Others
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    F. Hoffmann-La Roche 
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Mergers and Acquisitions
        21.1.5    Certifications
    21.2    Novartis AG 
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Mergers and Acquisitions
        21.2.5    Certifications
    21.3    GlaxoSmithKline PLC 
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Mergers and Acquisitions
        21.3.5    Certifications
    21.4    Sanofi SA
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Mergers and Acquisitions
        21.4.5    Certifications
    21.5    Pfizer Inc.
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Mergers and Acquisitions
        21.5.5    Certifications
22    Parasitic Diseases Therapeutics - Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global parasitic diseases therapeutics market reached a value of USD 1.79 billion in 2023.

The market is anticipated to grow at a CAGR of 5% during the forecast period of 2024-2032 to reach a value of USD 2.77 billion by 2032.

The major drivers of the industry include rising disposable incomes, increasing population, and the rising prevalence of parasites.

The rising initiatives and programmes to eliminate parasitic diseases is expected to be a key trend guiding the growth of the industry.

North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa are the leading regions in the market.

The major products of parasitic diseases therapeutics in the industry are antiprotozoal therapeutics, anthelminthic therapeutics, and scabicides and pediculicides therapeutics.

The leading players in the market are F. Hoffmann-La Roche, Novartis AG, GlaxoSmithKline PLC, Sanofi SA, and Pfizer Inc., among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER